Spherix Inc., a biotechnology company based in Maryland, announced results of its NEET Phase 3 study of D-tagatose as a monotherapy for type 2 diabetes.
The NEET (Naturlose® Efficacy Evaluation Trial) data showed a significant drop in Hemoglobin A1c (HbA1c) levels among patients treated with D-tagatose.
Patients in the study had a low average randomization HbA1c of 7.5% globally. An HbA1c level of 6% or below is considered normal. An 8% level is considered high. The American Diabetes Association recommends a goal of reducing HbA1c to 7% or below in people with diabetes.
For the full press release click here.
